Drug Profile


Alternative Names: CCR5 antagonists - Merck; Merck compound A

Latest Information Update: 30 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Amino acids; Antiretrovirals; Pyrazoles
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV-1 infections; Transplant rejection

Most Recent Events

  • 10 Sep 2004 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
  • 10 Sep 2004 Preclinical trials in Transplant rejection in USA (unspecified route)
  • 10 Sep 2004 Data presented at the 228th American Chemical Society National Meeting - (228th-ACS-2004) have been added to the Transplant Rejection pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top